The assessment of metabolic syndrome in UK patients with HIV using two different definitions: CREATE 2 study

References

• Carr A, Miller J, Law M, et al. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000;14:F25-F32
   PubMed Web of Science ®Google Scholar
• Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32:130-9
   PubMed Web of Science ®Google Scholar
• Kulasegaram R, Peters BS, Wierzbicki AS. Dyslipidaemia and cardiovascular risk in HIV infection. Curr Med Res Opin 2005;21:1717-25
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Purdon SD, Hardman TC, et al. HIV lipodystrophy and its metabolic consequences: implications for clinical practice. Curr Med Res Opin 2008;24:609-24
   PubMed Web of Science ®Google Scholar
• Aboud M, Elgalib A, Kulasegaram R, et al. Insulin resistance and HIV infection: a review. Int J Clin Pract 2007;61:463-72
   PubMed Web of Science ®Google Scholar
• Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607
   PubMed Web of Science ®Google Scholar
• Miranda PJ, DeFronzo RA, Califf RM, et al. Metabolic syndrome: definition, pathophysiology, and mechanisms. Am Heart J 2005;149:33-45
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52
   PubMed Web of Science ®Google Scholar
• Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28
   PubMed Web of Science ®Google Scholar
• Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-19
   PubMed Web of Science ®Google Scholar
• McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005;28:385-90
   PubMed Web of Science ®Google Scholar
• Sundstrom J, Riserus U, Byberg L et al. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 2006;332:878-82
   Google Scholar
• Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16
   PubMed Web of Science ®Google Scholar
• Hu G, Qiao Q, Tuomilehto J, et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004;164:1066-76
   PubMed Web of Science ®Google Scholar
• Zimmet P. Epidemiology of diabetes mellitus and associated cardiovascular risk factors: focus on human immunodeficiency virus and psychiatric disorders. Am J Med 2005;118(Suppl. 2):3S-8S
   PubMedGoogle Scholar
• Alberti KG, Zimmet P, Shaw J. The metabolic syndrome – a new worldwide definition. Lancet 2005;366:1059-62
   PubMed Web of Science ®Google Scholar
• Eckel RH, Alberti KG, Grundy SM, et al. The metabolic syndrome. Lancet 2010;375:181-3
   PubMed Web of Science ®Google Scholar
• Wilson S, Johnston A, Robson J, et al. Comparison of methods to identify individuals at increased risk of coronary disease from the general population. BMJ 2003;326:1436
   PubMed Web of Science ®Google Scholar
• Unwin N, Bhopal R, Hayes L, et al. A comparison of the new international diabetes federation definition of metabolic syndrome to WHO and NCEP definitions in Chinese, European and South Asian origin adults. Ethn Dis 2007;17:522-8
   PubMed Web of Science ®Google Scholar
• Jerico C, Knobel H, Montero M, et al. Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care 2005;28:132-7
   PubMed Web of Science ®Google Scholar
• Mondy K, Overton ET, Grubb J, et al. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis 2007;44:726-34
   PubMed Web of Science ®Google Scholar
• Samaras K, Wand H, Law M, et al. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive peptide, and hypoadiponectinemia. Diabetes Care 2007;30:113-19
   PubMed Web of Science ®Google Scholar
• Bonfanti P, Ricci E, de Socio G, et al. Metabolic syndrome: a real threat for HIV-positive patients?: Results from the SIMONE study. J Acquir Immune Defic Syndr 2006;42:128-31
   PubMed Web of Science ®Google Scholar
• Jacobson DL, Tang AM, Spiegelman D, et al. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr 2006;43:458-66
   PubMed Web of Science ®Google Scholar
• Bonfanti P, Giannattasio C, Ricci E, et al. HIV and metabolic syndrome: a comparison with the general population. J Acquir Immune Defic Syndr 2007;45:426-31
   PubMed Web of Science ®Google Scholar
• Bruno R, Gazzaruso C, Sacchi P, et al. High prevalence of metabolic syndrome among HIV-infected patients: link with the cardiovascular risk. J Acquir Immune Defic Syndr 2002;31:363-5
   PubMed Web of Science ®Google Scholar
• Gazzaruso C, Sacchi P, Garzaniti A, et al. Prevalence of metabolic syndrome among HIV patients. Diabetes Care 2002;25:1253-4
   PubMed Web of Science ®Google Scholar
• Worm SW, Friis-Moller N, Bruyand M, et al. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS 2010;24:427-35
   PubMed Web of Science ®Google Scholar
• Bernal E, Masia M, Padilla S, et al. [Prevalence and characteristics of metabolic syndrome among HIV-infected patients from a Mediterranean cohort]. Med Clin (Barc) 2007;128:172-5
   PubMed Web of Science ®Google Scholar
• Hansen BR, Petersen J, Haugaard SB, et al. The prevalence of metabolic syndrome in Danish patients with HIV infection: the effect of antiretroviral therapy. HIV Med 2009;10:378-87
   PubMed Web of Science ®Google Scholar
• Bonfanti P, De Socio GL, Marconi P, et al. Is metabolic syndrome associated to HIV infection per se? Results from the HERMES study. Curr HIV Res 2010;8:165-71
   PubMed Web of Science ®Google Scholar
• Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093-9
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53
   PubMed Web of Science ®Google Scholar
• Carr A, Hudson J, Chuah J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS 2001;15:1811-22
   PubMed Web of Science ®Google Scholar
• Calza L, Manfredi R, Chiodo F. Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. Int J Antimicrob Agents 2003;22:89-99
   PubMed Web of Science ®Google Scholar
• Calza L, Manfredi R, Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 2004;53:10-14
   PubMed Web of Science ®Google Scholar
• Franssen R, Sankatsing RR, Hassink E, et al. Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. Arterioscler Thromb Vasc Biol 2009;29:1336-41
   PubMed Web of Science ®Google Scholar
• Gazzaruso C, Bruno R, Garzaniti A, et al. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens 2003;21:1377-82
   PubMed Web of Science ®Google Scholar
• Gaillard T, Schuster D, Osei K. Differential impact of serum glucose, triglycerides, and high-density lipoprotein cholesterol on cardiovascular risk factor burden in nondiabetic, obese African American women: implications for the prevalence of metabolic syndrome. Metabolism 2010; published online, doi:S0026-0495(09)00478-8 [pii];10.1016/j.metabol.2009.09.035 [doi]
   Google Scholar
• van der Merwe MT, Crowther NJ, Schlaphoff GP, et al. Evidence for insulin resistance in black women from South Africa. Int J Obes Relat Metab Disord 2000;24:1340-6
   PubMed Web of Science ®Google Scholar
• Keiser PH, Sension MG, DeJesus E, et al. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment. BMC Infect Dis 2005;5:2
   PubMed Web of Science ®Google Scholar